EMA seeks greater engagement with industry to connect silos

By Natalie Morrison

- Last updated on GMT

EMA seeks greater engagement with industry to connect silos

Related tags Pharmacology Regulation European medicines agency

The EMA wants greater engagement from the drug industry to help it modernise regulation and join the "unconnected boxes" that separate stakeholders. 

Speaking to Outsourcing-Pharma at DIA Euromeeting in Denmark, Guido Rasi, executive director at the European Medicines Agency (EMA), said better communication between regulators, patients and industry is needed to modernise pharmaceutical oversight. The EMA is currently focussing on doing just that.

However, he said the initiative’s success requires industry to step-up its involvement in the formation of the regulatory process. “The only stakeholder that is not now in the agency is the industry, but we do have a forum where we can discuss with them and include them,”​ he said.

“All the other stakeholders are really in the agency: the patient, the professionals, the commission representative from parliament – we have all the stakeholders potentially.”

He added that he feels “the time is now for a higher level of engagement”.

Know your place

The backbone of the EMA’s new efforts to change the regulatory process is ensuring each player understands its role within the process.

Martin Harvey, head of communications for the EMA, told us the body is starting by taking a good hard look at itself.

He said: “What the EMA wants to achieve is a better understanding about the regulators’ role in the chain.

“Quite often we feel like we’re in unconnected boxes. Health payers there, industry there, patients there.

“The question we’re asking ourselves at the moment is what information is needed from the regulators and what is needed from the pharma industry, and how do we join all of this together?”

He added that in the EMA’s new paradigm, everyone is the process is equally important, “the question is: how do you involve everybody?”

Related topics Clinical Development Phase III-IV

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Webinars

Headlines